Paper42017407
Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.
Joshi S and 7 others. Headache, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study. Papers, record 42017407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42017407
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Migraine Disorders | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Topiramate | Major topic |
| Amitriptyline | Major topic |
| Humans | |
| Treatment Outcome | |
| Female | |
| Male | |
| Adult | |
| Administration, Oral | |
| Middle Aged |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Eli Lilly and Company | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33267788 | Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. | J Headache Pain | 2020 | https://conductscience.org/library/papers/33267788 | PubMed |
| 2 | 42017407 | Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study. | Headache | 2026 | https://conductscience.org/library/papers/42017407 | PubMed |
| 3 | 14152626 | TREATMENT OF CHRONIC TENSION HEADACHE. | Lancet | 1964 | https://conductscience.org/library/papers/14152626 | PubMed |
| 4 | 22671714 | The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. | Headache | 2012 | https://conductscience.org/library/papers/22671714 | PubMed |
| 5 | 41224245 | Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). | Pharmacoepidemiol Drug Saf | 2025 | https://conductscience.org/library/papers/41224245 | PubMed |
| 6 | 30536394 | The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. | Headache | 2019 | https://conductscience.org/library/papers/30536394 | PubMed |
| 7 | 29813147 | Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. | JAMA Neurol | 2018 | https://conductscience.org/library/papers/29813147 | PubMed |
| 8 | 34743579 | Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. | Cephalalgia | 2022 | https://conductscience.org/library/papers/34743579 | PubMed |
| 9 | 32209650 | Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. | Neurology | 2020 | https://conductscience.org/library/papers/32209650 | PubMed |
| 10 | 37792218 | Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE. | Neurol Ther | 2023 | https://conductscience.org/library/papers/37792218 | PubMed |
| 11 | 32183872 | Adverse drug reactions associated with amitriptyline - protocol for a systematic multiple-indication review and meta-analysis. | Syst Rev | 2020 | https://conductscience.org/library/papers/32183872 | PubMed |
| 12 | 22683887 | Canadian Headache Society guideline for migraine prophylaxis. | Can J Neurol Sci | 2012 | https://conductscience.org/library/papers/22683887 | PubMed |
| 13 | 32722936 | Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. | Cephalalgia | 2020 | https://conductscience.org/library/papers/32722936 | PubMed |
| 14 | 35410119 | The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. | J Headache Pain | 2022 | https://conductscience.org/library/papers/35410119 | PubMed |
| 15 | 29368949 | Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. | Cephalalgia | 2018 | https://conductscience.org/library/papers/29368949 | PubMed |
| 16 | 31563224 | Migraine: Epidemiology, Burden, and Comorbidity. | Neurol Clin | 2019 | https://conductscience.org/library/papers/31563224 | PubMed |
| 17 | 35690723 | European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. | J Headache Pain | 2022 | https://conductscience.org/library/papers/35690723 | PubMed |
| 18 | 34145431 | Diagnosis and management of migraine in ten steps. | Nat Rev Neurol | 2021 | https://conductscience.org/library/papers/34145431 | PubMed |
| 19 | 41017292 | Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study. | Headache | 2026 | https://conductscience.org/library/papers/41017292 | PubMed |
| 20 | 35687795 | Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. | Brain Behav | 2022 | https://conductscience.org/library/papers/35687795 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42017407 | Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study. | Headache | 2026 | https://conductscience.org/library/papers/42017407 |
Source PubMed
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| EudraCT | EUPAS33068 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42017407
GET https://conductscience.org/api/papers/v1/42017407/references?page=2